JAK Inhibitors in Atopic Dermatitis
A panel of dermatologists discuss the evolution of JAK inhibitors for atopic dermatitis and how they fit into current treatment paradigms.
EP: 1.Heterogenous Presentation of Atopic Dermatitis
EP: 2.Burden of Atopic Dermatitis and its Impact on Patient’s Quality of Life
EP: 3.Patient’s Goals and Atopic Dermatitis Treatment Selection
EP: 4.Talking to Patients about Atopic Dermatitis Treatment Response
EP: 5.Use of PRO in Atopic Dermatitis Clinical Practice
EP: 6.Incorporating Patient Preferences in the Treatment of Atopic Dermatitis
EP: 7.Changing Standard of Care in Atopic Dermatitis
EP: 8.Unmet Needs and Gaps in AD
EP: 9.Looking Beyond Type 2 Inflammation in Atopic Dermatitis
Now Viewing
EP: 10.JAK Inhibitors in Atopic Dermatitis
Video content above is prompted by the following:
- A number of JAK inhibitors, both oral (abrocitinib, upadacitnib) and topical (ruxolitinib cream), are FDA approved for atopic dermatitis.
- How have JAK inhibitors evolved over the years?
- How have differences between JAK inhibitors led to differences in their safety and efficacy profiles?
Recent Videos
Related Content
